Onset of eczema between 4 and 6 months, greater severity, and longer duration linked to lower likelihood of outgrowing allergies
FRIDAY, Nov. 7, 2025 (HealthDay News) — The likelihood of outgrowing food allergy (FA) is reduced in association with the onset of eczema at 4 to 6 months, greater severity, and longer duration, according to a study presented at the annual meeting of the American College of Allergy, Asthma & Immunology, held from Nov. 6 to 10 in Orlando, Florida.
Nicole Koulov, from the University of Texas in Houston, and colleagues examined the effects of eczema onset timing, duration, and severity on subsequent development of oral tolerance in children aged 0 to 12 years with a history of outgrown immunoglobulin E-mediated FA.
The researchers found that models estimated a significant nonlinear association between eczema duration and FA duration among 855 pediatric patients with eczema, with the predicted probability of outgrowing an allergy decreasing at lower durations, increasing with durations between eight and 10 years, then decreasing again. The odds of outgrowing an FA were lower in association with greater eczema severity. Children whose eczema began at 4 to 6 months of age had significantly lower odds of resolution compared with those with onset at 0 to 3 months; no significant difference was seen for later-onset groups.
“These findings show that eczema is more than just a coexisting condition — it may directly influence whether children overcome food allergies,” coauthor Amal Assa”ad, M.D., of the Cincinnati Children”s Hospital Medical Center, said in a statement. “Our data suggest that the timing and management of eczema could be an important factor in helping children develop tolerance.”
Risk for Herpes Zoster Elevated for Individuals With Atopic Dermatitis
Early Respiratory Infections Linked to Atopic Dermatitis Diagnosis
Review Shows Antihistamines Offer No Meaningful Benefit in Atopic Dermatitis
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine
CDC: Seroprevalence of Alpha-Gal IgE Antibodies Highest in States With Elevated Case Counts
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS